Cargando…

Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events

BACKGROUND: Comorbidities including ischemic heart disease (IHD) worsen outcomes after SARS‐CoV‐2 infections. High lipoprotein(a) [Lp(a)] concentrations are a strong risk factor for IHD and possibly for thromboembolic events. We therefore evaluated whether SARS‐CoV‐2 infections modify the risk of hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Maio, Silvia, Lamina, Claudia, Coassin, Stefan, Forer, Lukas, Würzner, Reinhard, Schönherr, Sebastian, Kronenberg, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242884/
https://www.ncbi.nlm.nih.gov/pubmed/34096654
http://dx.doi.org/10.1111/joim.13338
_version_ 1783715662140538880
author Di Maio, Silvia
Lamina, Claudia
Coassin, Stefan
Forer, Lukas
Würzner, Reinhard
Schönherr, Sebastian
Kronenberg, Florian
author_facet Di Maio, Silvia
Lamina, Claudia
Coassin, Stefan
Forer, Lukas
Würzner, Reinhard
Schönherr, Sebastian
Kronenberg, Florian
author_sort Di Maio, Silvia
collection PubMed
description BACKGROUND: Comorbidities including ischemic heart disease (IHD) worsen outcomes after SARS‐CoV‐2 infections. High lipoprotein(a) [Lp(a)] concentrations are a strong risk factor for IHD and possibly for thromboembolic events. We therefore evaluated whether SARS‐CoV‐2 infections modify the risk of high Lp(a) concentrations for IHD or thromboembolic events during the first 8.5 months follow‐up of the pandemic. METHOD: Cohort study using data from the UK Biobank during the SARS‐CoV‐2 pandemic. Baseline Lp(a) was compared between SARS‐CoV‐2 positive patients and the population controls. RESULTS: SARS‐CoV‐2 positive patients had Lp(a) concentrations similar to the population controls. The risk for IHD increased with higher Lp(a) concentrations in both, the population controls (n = 435,104) and SARS‐CoV‐2 positive patients (n = 6937). The causality of the findings was supported by a genetic risk score for Lp(a). A SARS‐CoV‐2 infection modified the association with a steeper increase in risk for infected patients (interaction p‐value = 0.03). Although SARS‐CoV‐2 positive patients had a five‐times higher frequency of thromboembolic events compared to the population controls (1.53% vs. 0.31%), the risk was not influenced by Lp(a). CONCLUSIONS: SARS‐CoV‐2 infections enforce the association between high Lp(a) and IHD but the risk for thromboembolic events is not influenced by Lp(a).
format Online
Article
Text
id pubmed-8242884
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82428842021-07-01 Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events Di Maio, Silvia Lamina, Claudia Coassin, Stefan Forer, Lukas Würzner, Reinhard Schönherr, Sebastian Kronenberg, Florian J Intern Med Brief Reports BACKGROUND: Comorbidities including ischemic heart disease (IHD) worsen outcomes after SARS‐CoV‐2 infections. High lipoprotein(a) [Lp(a)] concentrations are a strong risk factor for IHD and possibly for thromboembolic events. We therefore evaluated whether SARS‐CoV‐2 infections modify the risk of high Lp(a) concentrations for IHD or thromboembolic events during the first 8.5 months follow‐up of the pandemic. METHOD: Cohort study using data from the UK Biobank during the SARS‐CoV‐2 pandemic. Baseline Lp(a) was compared between SARS‐CoV‐2 positive patients and the population controls. RESULTS: SARS‐CoV‐2 positive patients had Lp(a) concentrations similar to the population controls. The risk for IHD increased with higher Lp(a) concentrations in both, the population controls (n = 435,104) and SARS‐CoV‐2 positive patients (n = 6937). The causality of the findings was supported by a genetic risk score for Lp(a). A SARS‐CoV‐2 infection modified the association with a steeper increase in risk for infected patients (interaction p‐value = 0.03). Although SARS‐CoV‐2 positive patients had a five‐times higher frequency of thromboembolic events compared to the population controls (1.53% vs. 0.31%), the risk was not influenced by Lp(a). CONCLUSIONS: SARS‐CoV‐2 infections enforce the association between high Lp(a) and IHD but the risk for thromboembolic events is not influenced by Lp(a). John Wiley and Sons Inc. 2021-10-29 2022-01 /pmc/articles/PMC8242884/ /pubmed/34096654 http://dx.doi.org/10.1111/joim.13338 Text en © 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Reports
Di Maio, Silvia
Lamina, Claudia
Coassin, Stefan
Forer, Lukas
Würzner, Reinhard
Schönherr, Sebastian
Kronenberg, Florian
Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events
title Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events
title_full Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events
title_fullStr Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events
title_full_unstemmed Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events
title_short Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events
title_sort lipoprotein(a) and sars‐cov‐2 infections: susceptibility to infections, ischemic heart disease and thromboembolic events
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242884/
https://www.ncbi.nlm.nih.gov/pubmed/34096654
http://dx.doi.org/10.1111/joim.13338
work_keys_str_mv AT dimaiosilvia lipoproteinaandsarscov2infectionssusceptibilitytoinfectionsischemicheartdiseaseandthromboembolicevents
AT laminaclaudia lipoproteinaandsarscov2infectionssusceptibilitytoinfectionsischemicheartdiseaseandthromboembolicevents
AT coassinstefan lipoproteinaandsarscov2infectionssusceptibilitytoinfectionsischemicheartdiseaseandthromboembolicevents
AT forerlukas lipoproteinaandsarscov2infectionssusceptibilitytoinfectionsischemicheartdiseaseandthromboembolicevents
AT wurznerreinhard lipoproteinaandsarscov2infectionssusceptibilitytoinfectionsischemicheartdiseaseandthromboembolicevents
AT schonherrsebastian lipoproteinaandsarscov2infectionssusceptibilitytoinfectionsischemicheartdiseaseandthromboembolicevents
AT kronenbergflorian lipoproteinaandsarscov2infectionssusceptibilitytoinfectionsischemicheartdiseaseandthromboembolicevents